AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CytoDyn, Inc.
CytoDyn Files New IND for Cytolin
November 3rd, 2008
CytoDyn, Inc. (Pink Sheets:CYDY) has filed a new IND for a study to reconfirm dose ranging and to "prove the principle" with a randomized, double-blind placebo controlled study of Cytolin(R), the Company's first-in-class drug for treating HIV/AIDS. This comes 13 years after the first IND was issued for the drug. Initially, Cytolin(R) was used experimentally by community physicians to rescue 200 - 300 AIDS patients over a period of two years before the antiretroviral cocktails had become available, as reported by CBS-TV News. Subsequently, the drug's inventor and his associates learned the pitfalls of out-licensing technology in an environment where innumeracy created a fertile field for...
Source: AIDS Weekly (2008-11-03)
|
